Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Thrombocytosis (platelets > 450 G/L)

Haematology · Abnormal laboratory result · updated 2026-10-31

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: 1.5 to 2.2% of primary care attenders aged 40 or over [1]

Platelets > 450 G/L without severity signs: initial tests

Laboratory tests

Imaging

In 4 to 6 weeks

Detailed explanation and international comparison (in French): read it in English (machine translation)

Persistent unexplained thrombocytosis: before referral

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Severity sign: urgent haematology advice

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (17)
  1. Bailey SE, Ukoumunne OC, Shephard EA, Hamilton W. Clinical relevance of thrombocytosis in primary care: a prospective cohort study of cancer incidence using English electronic medical records and cancer registry data. Br J Gen Pract. 2017;67(659):e405-e413.
  2. NHS Lothian. RefHelp : Thrombocytosis (haematology referral guideline), version du 2 décembre 2025.
  3. Humber and North Yorkshire Policy and Pathway Repository (York). Thrombocytosis pathway. Dr A. Whittle, hématologue ; modifié le 16 septembre 2025 (révision prévue en 2027).
  4. National Institute for Health and Care Excellence. Suspected cancer: recognition and referral (NG12). Publiée le 23 juin 2015, mise à jour le 15 avril 2026 : recommandations 1.1.3, 1.2.3, 1.2.9 et 1.5.13.
  5. Griesshammer M, Bangerter M, Sauer T, et al. Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med. 1999;245(3):295-300.
  6. Liautard C, Nunes AM, Vial T, et al. Low-molecular-weight heparins and thrombocytosis. Ann Pharmacother. 2002;36(9):1351-4.
  7. Frye JL, Thompson DF. Drug-induced thrombocytosis. J Clin Pharm Ther. 1993;18(1):45-8.
  8. Clarke C, Hamilton W, Price S, Bailey SER. Association of non-malignant diseases with thrombocytosis: a prospective cohort study in general practice. Br J Gen Pract. 2020;70(701):e852-e857.
  9. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : acte 1213 (ferritine) ; absence d'acte JAK2, CALR et MPL.
  10. Vora AJ, Lilleyman JS. Secondary thrombocytosis. Arch Dis Child. 1993;68(1):88-90.
  11. Williams PM, Williams AL. Thrombocytosis: Rapid Evidence Review. Am Fam Physician. 2026;113(4):332-338.
  12. Barbui T, Thiele J, Gisslinger H, et al. The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion. Blood Cancer J. 2018;8(2):15.
  13. Petrides PE, Baerlocher GM, Döhner K, Gisslinger H, Grießhammer M, Koschmieder S, Schwaab J, et al. Essentielle (oder primäre) Thrombozythämie (ET). Leitlinie Onkopedia (DGHO), décembre 2023.
  14. Agence du numérique en santé. Terminologie LAHN (liste des actes innovants hors nomenclature de biologie et d'anatomopathologie), version 2026-04 : codes N417 et N455.
  15. Buss DH, Cashell AW, O'Connor ML, Richards F 2nd, Case LD. Occurrence, etiology, and clinical significance of extreme thrombocytosis: a study of 280 cases. Am J Med. 1994;96(3):247-53.
  16. Humber and North Yorkshire Policy and Pathway Repository (York). Thrombocytosis pathway. (liste des causes)
  17. Frye JL, Thompson DF. Drug-induced thrombocytosis. J Clin Pharm Ther. 1993;18(1):45-8. (résumé)